<<Shares of Optimer Pharmaceuticals (NASDAQ:OPTR) traded today at $17.95, breaking its 52-week high. This new high was reached on above average trading volume as 2.9 million shares traded hands, while the average 30-day volume is approximately 1.3 million shares.>>>
Yikes. I sold at near the top and bought back near the bottom. What a swing that was. Now I am primed again for the ride up.
I'm not sure what the end target will be, but I am sure that upgrades will be coming -- along with speculation will come with that.
I am sure that this is a much needed drug to combat the the difficulties in curing C-DAD. I am sure that the EMA will approve DIFICLIR, but I don't know what kind of schedule they have for approvals. In the meantime, Optimer is getting its sales and distribution set up.
So, what is the short position? Hmm.
<<STAINES, England and SAN DIEGO, California, September 23, 2011 /PRNewswire/ -- Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR(TM) (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).>>